NMRA
Neumora Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$329.81M
P/E Ratio
—
EPS
$-1.33
Beta
3.05
52W High
$3.65
52W Low
$0.72
50-Day MA
$1.99
200-Day MA
$2.20
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-217.98M |
| Operating Margin | 0.00% |
| Return on Equity | -121.20% |
| Return on Assets | -58.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.60 |
| Price-to-Book | 4.67 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $185.28M |
| Float | $104.83M |
| % Insiders | 23.60% |
| % Institutions | 57.91% |
Historical Volatility
HV 10-Day
73.81%
HV 20-Day
68.46%
HV 30-Day
87.36%
HV 60-Day
83.82%
HV Rank
36.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.91 target)
2
Strong Buy5
Buy1
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026